Divi’s Laboratories Ltd reported a healthy operational performance for the quarter ended March 2026, supported by higher revenue, improved EBITDA and a sharp jump in forex gains during the period. The company also announced a final dividend recommendation of ₹30 per equity share for FY26.
Revenue from operations during Q4FY26 stood at ₹2,831 crore, compared to ₹2,588 crore reported in the corresponding quarter last year, registering a growth of around 9.4% YoY. Profit after tax for the quarter came in at ₹751 crore against ₹662 crore in Q4FY25.
Based on the company’s reported financials, EBITDA for the quarter was calculated at ₹934 crore, compared to ₹889 crore in the year-ago quarter. EBITDA margin stood at 33.0% in Q4FY26 versus 34.4% in Q4FY25.
The company said forex gains supported quarterly profitability. For the current quarter, Divi’s Laboratories recorded a forex gain of ₹90 crore as against a forex gain of ₹10 crore during the corresponding quarter of the previous year.
Total income for the quarter rose to ₹2,986 crore from ₹2,671 crore a year earlier, while total expenses increased to ₹2,023 crore from ₹1,807 crore.
For the full financial year FY26, revenue from operations stood at ₹10,560 crore compared to ₹9,360 crore in FY25. Net profit for the year came in at ₹2,568 crore against ₹2,191 crore in the previous financial year.
The Board of Directors at its meeting held on May 23, 2026, recommended a dividend of ₹30 per equity share having a face value of ₹2 each, translating into a 1500% dividend payout for FY26, subject to shareholders’ approval at the ensuing Annual General Meeting.
Disclaimer: This article is based on company exchange filings and financial disclosures. Investors are advised to consult certified financial advisors before making investment decisions.